TY - JOUR
T1 - Circulating tumour cells and cell-free DNA as tools for managing breast cancer
AU - De Mattos-Arruda, Leticia
AU - Cortes, Javier
AU - Santarpia, Libero
AU - Vivancos, Ana
AU - Tabernero, Josep
AU - Reis-Filho, Jorge S.
AU - Seoane, Joan
PY - 2013/7
Y1 - 2013/7
N2 - Circulating blood biomarkers promise to become non-invasive real-time surrogates for tumour tissue-based biomarkers. Circulating biomarkers have been investigated as tools for breast cancer diagnosis, the dissection of breast cancer biology and its genetic and clinical heterogeneity, prognostication, prediction and monitoring of therapeutic response and resistance. Circulating tumour cells and cell-free plasma DNA have been analysed in retrospective studies, and the assessment of these biomarkers is being incorporated into clinical trials. As the scope of breast cancer intratumour genetic heterogeneity unravels, the development of robust and standardized methods for the assessment of circulating biomarkers will be essential for the realization of the potentials of personalized medicine. In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer.
AB - Circulating blood biomarkers promise to become non-invasive real-time surrogates for tumour tissue-based biomarkers. Circulating biomarkers have been investigated as tools for breast cancer diagnosis, the dissection of breast cancer biology and its genetic and clinical heterogeneity, prognostication, prediction and monitoring of therapeutic response and resistance. Circulating tumour cells and cell-free plasma DNA have been analysed in retrospective studies, and the assessment of these biomarkers is being incorporated into clinical trials. As the scope of breast cancer intratumour genetic heterogeneity unravels, the development of robust and standardized methods for the assessment of circulating biomarkers will be essential for the realization of the potentials of personalized medicine. In this Review, we discuss the current status of blood-born biomarkers as surrogates for tissue-based biomarkers, and their burgeoning impact on the management of patients with breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=84879796970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879796970&partnerID=8YFLogxK
U2 - 10.1038/nrclinonc.2013.80
DO - 10.1038/nrclinonc.2013.80
M3 - Article
C2 - 23712187
AN - SCOPUS:84879796970
VL - 10
SP - 377
EP - 389
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
SN - 1759-4774
IS - 7
ER -